Acquisitions (Tables)

9 Months Ended

Sep. 30, 2017

Schedule of proforma results

	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
	September 30,		September 30,		September 30,		September 30,
	2017		2016		2017		2016
Revenue	$	39,420	$	31,266	$	112,079	$	85,336
Net loss		(727)		(1,332)		(5,098)		(4,259)
Net income (loss) per share attributable to common stockholders, basic		(0.04)		0.12		(0.30)		(0.32)
Net loss per share attributable to common stockholders, diluted		(0.04)		(0.17)		(0.30)		(0.44)

SinfoniaRx

Schedule of purchase price consideration

Cash consideration at closing, net of post-closing adjustments	$	34,670
Stock consideration at closing		11,541
Estimated fair value of contingent consideration		26,406
Total fair value of acquisition consideration	$	72,617

Schedule of allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities

Cash	$	218
Accounts receivable		8,309
Prepaid expenses and other current assets		1,001
Property and equipment		1,419
Other assets		94
Trade name		4,429
Developed technology		12,640
Client relationships		19,579
Non-competition agreement		4,497
Goodwill		41,439
Total assets acquired	$	93,625
Accrued expenses and other liabilities		(2,667)
Trade accounts payable		(8,769)
Debt assumed		(675)
Deferred income tax liability		(8,897)
Total purchase price, including contingent consideration of $26,406	$	72,617